We are problem-oriented and have a tumor-centric view that rests on well-established concepts developed by researchers around the world. We aim to identify and challenge the barriers to sustainable patient benefit from current effective melanoma therapies.
Our current research is focused on identification and characterization of cues that either preclude or afford therapeutic responses in melanoma patients and as biomarkers can inform treatment.
Mechanisms that drive long-term responses to BRAF(V600E)-targeted therapies in melanoma
How melanoma tumors coerce an active immune microenvironment to evade checkpoint blockage